Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this Phase IIa trial is to determine the effective dose and
treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression
disorder (MDD). The secondary objectives of this trial are to evaluate the safety and quality
of life in subjects with MDD receiving RX-10100 treatment.